title: New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland.
abstract: Starting in 2008 a new designer drug, 3,4-methylenedioxypyrovalerone (MDPV) appeared among users of illegal drugs in Finland. Since then there have been several seizures of MDPV by police and customs and it has been connected to many crimes of different types. In this study the incidence and impact of the use of MDPV in drivers suspected of being under the influence of drugs (DUID) in Finland was assessed. Since autumn 2009, blood samples from drivers suspected of DUID in Finland have been analysed for the presence of MDPV. A new LC-MS/MS method for the determination of MDPV in serum was established. In order to assess the impact of MDPV on driving performance, drug and alcohol findings of positive MDPV cases were compared with data from the clinical examination carried out while the suspect was under arrest. In a period of one year there were 259 positive MDPV cases from apprehended drivers (5.7% of all confirmed DUID cases). In 80% of the cases in which MDPV was found, amphetamine was also present. Benzodiazepines were also frequently found together with MDPV, which was to be expected since in Finland, in our experience, stimulants are very often used together with benzodiazepines. In most cases it remained unclear whether the observed psycho-physical achievement deficiency was induced by MDPV because the concentrations of other drugs, especially other stimulants, were often high. However, in some subjects, MDPV, or MDPV in combination with other substances was the most probable cause of the impairment. The concentrations of MDPV varied from 0.016mg/L to over 8.000mg/L. Little is known about the pharmacology of MDPV. However, based on our findings it is clear that MDPV has a serious impact on traffic safety in Finland.
authors.affiliation: Vita Health Care Services Ltd., Vita Laboratory, Laivakatu 5 F, 00150 Helsinki, Finland. pirkko.kriikku@vita.fi
authors.forename: Pirkko
authors.initials: P
authors.lastname: Kriikku
authors.forename: Lars
authors.initials: L
authors.lastname: Wilhelm
authors.forename: Olaf
authors.initials: O
authors.lastname: Schwarz
authors.forename: Janne
authors.initials: J
authors.lastname: Rintatalo
mesh_terms: D001334:Automobile Driving / Q000331:legislation & jurisprudence*; D052117:Benzodioxoles / Q000097:blood* / Q000737:chemistry; D002853:Chromatography, Liquid; D015198:Designer Drugs; D005387:Finland / Q000453:epidemiology; D053593:Forensic Toxicology; D006801:Humans; D057230:Limit of Detection; D013058:Mass Spectrometry; D015394:Molecular Structure; D011619:Psychotropic Drugs / Q000097:blood* / Q000737:chemistry; D011759:Pyrrolidines / Q000097:blood* / Q000737:chemistry; D015813:Substance Abuse Detection; D019966:Substance-Related Disorders / Q000453:epidemiology; D000094982:Synthetic Cathinone
chemical_list: D052117:Benzodioxoles; D015198:Designer Drugs; D011619:Psychotropic Drugs; D011759:Pyrrolidines; D000094982:Synthetic Cathinone